Last week, alongside Dr. Aundrea Oliver and my colleague Dr. Julia Elvin, I had the chance to meet local policy makers at our site in Research Triangle Park, N.C., and have a discussion about the value of high-quality biomarker testing and the role it plays in precision oncology.

Spent some time w/ our lab employees this week as part of #LabWeek2023 and heard from one of our patient advocates, Summer (Summer Farmen). This team of world-class scientists is the engine of Foundation Medicine. Thank you, for everything you do for us, our partners, and our patients!

An incredibly well-deserved honor. Congrats, Christine Lovly, MD, PhD, FASCO!

Companion diagnostics are critical for the safe and effective use of targeted therapies. This approval is another great example of our commitment to improving access to high-quality genomic testing in the clinic. Congrats to the team at Foundation Medicine and our partners at Takeda!

Proud of the work we’re doing to be a socially and environmentally responsible organization!

It was such an honor to ring the Nasdaq Closing Bell with Global Coalition for Adaptive Research on Friday as part of #BrainCancerAwarenessMonth! Proud of the work this organization is doing to enable a faster learning environment and more efficient drug development. #GoGrayinMay

As the science of cancer and the technologies used to treat it become more complex, regulators and payers are critical to help set a high bar for how companion diagnostics are valued and evaluated. My thoughts on what makes a high-quality test here: foundationmedicine.com/blog/an-inflec…

Thank you White House Office of Science & Technology Policy for bringing together the best and the brightest of the #braintumorcommunity to advance better outcomes for patients with #braincancer Meredith Buxton, Tim Cloughesy, @DrAlfredYung, David Arons, John de Groot, MD, Michael Lim, MD, and Liz Salmi at the White House

Really exciting to see the breadth of research on cancer monitoring, liquid biopsy, and complex genomic signatures being presented by Foundation Medicine and our collaborators at #ASCO23.

Really looking forward to speaking with STAT' Matthew Herper about the critical role high-quality diagnostics play in advancing our understanding of cancer and how we treat it at #ASCO23. Registration is still open if you’re interested in joining us onsite!

Spent the afternoon packing hygiene kits for a great organization, Boston Health Care for the Homeless Program, at our Cambridge site last week as part of Foundation Medicine's Week of Service. Huge thank you to all of our employees who spent time serving their local communities as part of this effort!

Our tissue-naïve monitoring test, FoundationOne Monitor is now available for research use in retrospective studies. This test will equip our research partners w/ another tool to learn about the experiences of patients & gather insights that we hope will transform drug development

Great discussion w/ Matthew Herper STAT about the important role high-quality diagnostics play in treating cancer as a disease of the genome and monitoring disease progression. It’s such an exciting time in oncology and I feel so privileged to be part of it. #ASCO23

We’re so proud to secure another companion diagnostic approval for FoundationOne Liquid CDx, reinforcing the quality of this test and its ability to match appropriate patients with a combination therapy for advanced colorectal cancer.

Proud to welcome these exceptional leaders to our Executive Team as we continue working to make molecular profiling indispensable to clinical care & research. These leaders are deeply committed to our mission & have broad expertise that will help us drive toward continued growth.

Proud that our CMO Mia Levy, MD, PhD has been elected to the @permedcoalition Board of Directors. PMC plays a critical role in connecting key stakeholders to improve access to precision medicine - looking forward to partnering w/ them more closely as they advance these important efforts

Congrats, Geoff Oxnard MD on this well-deserved honor!

Addressing disparities in cancer care requires collaboration and strong partnerships. We are proud to award the Moffitt Cancer Center and LUNGevity Foundation with a grant to remove barriers to information about personalized oncology for black patients. #healthequity

Excited to share the news of our collaboration to bring liquid biopsy genomic testing to patients in France.

We reached a significant milestone at Foundation Medicine with the launch of our new personalized tissue-informed circulating tumor DNA (ctDNA) monitoring test to monitor patients’ response to therapies.